Ftse Mib
38.655,30
1,73%
DAX
22.986,82
2,01%
S&P 500
5.638,94
2,13%
NASDAQ
17.754,09
2,61%
Bitcoin
84.180,21
-0,20%
Pepperstone
Advertisement
Registration Strip Icon for monitor Monitora più quotazioni in tempo reale dalle principali borse, come Borsa Italiana, NASDAQ, NYSE, AMEX, Bovespa e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Vir Biotechnology Inc (VIR) Vir Biotechnology Inc (VIR) Notizie

VIR

Vir Biotechnology (VIR)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:VIR
DataOraFonteTitoloSimboloCompagnia
27/02/202518:39Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIRVir Biotechnology Inc
27/02/202512:01Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:VIRVir Biotechnology Inc
26/02/202522:23Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VIRVir Biotechnology Inc
26/02/202522:17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIRVir Biotechnology Inc
26/02/202522:05Business WireVir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial ResultsNASDAQ:VIRVir Biotechnology Inc
19/02/202522:05Business WireVir Biotechnology to Participate in TD Cowen 45th Annual Health Care ConferenceNASDAQ:VIRVir Biotechnology Inc
12/02/202522:05Business WireVir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2024 Financial Results on February 26, 2025NASDAQ:VIRVir Biotechnology Inc
08/01/202513:45Business WireVir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPCNASDAQ:VIRVir Biotechnology Inc
18/12/202415:30Business WireVir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:VIRVir Biotechnology Inc
12/12/202422:05Business WireVir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis DeltaNASDAQ:VIRVir Biotechnology Inc
26/11/202415:30Business WireVir Biotechnology to Host Virtual Investor Event on PRO-XTEN™ Masked T-Cell Engager ProgramsNASDAQ:VIRVir Biotechnology Inc
25/11/202415:30Business WireVir Biotechnology to Participate in the 7th Annual Evercore ISI HealthCONx ConferenceNASDAQ:VIRVir Biotechnology Inc
19/11/202403:15Business WireVir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational ProgramNASDAQ:VIRVir Biotechnology Inc
18/11/202422:05Business WireVir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines AgencyNASDAQ:VIRVir Biotechnology Inc
15/11/202417:00Business WireVir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver MeetingNASDAQ:VIRVir Biotechnology Inc
04/11/202422:09Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VIRVir Biotechnology Inc
31/10/202421:05Business WireVir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:VIRVir Biotechnology Inc
17/10/202422:30Business WireVir Biotechnology to Provide Business Update and Report Third Quarter 2024 Financial Results on October 31, 2024NASDAQ:VIRVir Biotechnology Inc
15/10/202414:16Business WireVir Biotechnology Announces Clinical Advances Across Hepatitis Delta and Hepatitis B Programs at AASLD’s The Liver Meeting® 2024NASDAQ:VIRVir Biotechnology Inc
03/10/202423:11Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:VIRVir Biotechnology Inc
03/10/202422:00Business WireVir Biotechnology to Participate in the H.C. Wainwright 5th Annual Viral Hepatitis Virtual ConferenceNASDAQ:VIRVir Biotechnology Inc
10/09/202414:05Business WireVir Biotechnology Appoints Jason O’Byrne as Chief Financial OfficerNASDAQ:VIRVir Biotechnology Inc
09/09/202422:05Business WireVir Biotechnology Announces Closing of Exclusive Worldwide License Agreement With Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-Cell EngagersNASDAQ:VIRVir Biotechnology Inc
22/08/202414:05Business WireVir Biotechnology to Participate in the Morgan Stanley 22nd Annual Global Healthcare ConferenceNASDAQ:VIRVir Biotechnology Inc
01/08/202422:02Business WireVir Biotechnology Reports Second Quarter 2024 Financial Results and Announces Strategic Restructuring to Prioritize Clinical-Stage Pipeline OpportunitiesNASDAQ:VIRVir Biotechnology Inc
01/08/202422:01Business WireVir Biotechnology Acts on Expanded Strategy of Powering the Immune System Through Exclusive Worldwide License Agreement with Sanofi for Multiple Potential Best-in-Class Clinical-Stage T-cell EngagersNASDAQ:VIRVir Biotechnology Inc
18/07/202422:05Business WireVir Biotechnology to Report Second Quarter 2024 Financial Results on August 1, 2024NASDAQ:VIRVir Biotechnology Inc
26/06/202414:05Business WireVir Biotechnology Receives FDA IND Clearance and Fast Track Designation for Tobevibart and Elebsiran for the Treatment of Chronic Hepatitis Delta InfectionNASDAQ:VIRVir Biotechnology Inc
05/06/202411:30Business WireTobevibart Monotherapy and Combination Therapy with Elebsiran Achieved High Virologic Response and ALT Normalization in People Living with the Hepatitis Delta Virus After 12 and 24 Weeks of TreatmentNASDAQ:VIRVir Biotechnology Inc
29/05/202422:05Business WireVir Biotechnology to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceNASDAQ:VIRVir Biotechnology Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:VIR

La tua Cronologia

USOTC
AIIXY
Aixtron (PK)
BOV
ALPA3
ALPARGATAS ON
TSXV
BRN.PR.A
Brookfield Investments
BIT
UC3S9Z
Unicredit Bank
BIT
UI949C
Unicredit Bank
BIT
UC8E5S
Unicredit Bank
BIT
UI056D
Unicredit Bank
USOTC
FKCIF
Fukui Computer (PK)
HUOB
MXCUSDT
MXCToken
EU
LGJP
L&G Japan Equity UCITS ETF
NASDAQ
FIBUIX
Vest Nasdaq 100 Buffered...
EU
JPE3
WisdomTree Short JPY Lon...
COIN
INTERUSD
Inter Milan
USOTC
PSWW
Principal Solar (PK)
GATE
RAYUSD
Raydium
KUCN
DCCBTC
Distributed Credit Chain
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci